What's new

Singapore reports 1,939 COVID-19 cases, highest since April last year

Tai Hai Chen

ELITE MEMBER
Oct 15, 2017
20,931
-23
9,808
Country
Canada
Location
Canada

Sept 26 (Reuters) - Singapore's health ministry reported 1,939 new COVID-19 cases on Sunday, the highest since the beginning of the pandemic.

A recent rise in cases after the relaxation of some COVID-19 measures has prompted Singapore to pause further reopening. More than 80% of its population has been vaccinated against COVID-19.

Reporting by Juby Babu in Bengaluru; Editing by Toby Chopra
 
Last edited:

Tai Hai Chen

ELITE MEMBER
Oct 15, 2017
20,931
-23
9,808
Country
Canada
Location
Canada
After getting covid earlier this year, I am now half human half covid. And I never felt better. Zero covid is not a viable strategy. It is too expensive to test every person every day. Also, covid transmits in the air without symptoms. So it is nearly impossible to stop. Covid is not evil. Covid is simply the next step in human evolution. Rather than fight it, people should embrace it.


What do you think?

@White and Green with M/S @Mista @jamal18 @mike2000 is back @F-22Raptor @Hamartia Antidote @Suika @vostok @ChineseTiger1986 @beijingwalker @nang2 @UKBengali @925boy @gambit @hyperman @aziqbal @denel @Daniel808 @Menthol @Indos @TexasJohn
 
Last edited:

Viva_Viet

SENIOR MEMBER
Jun 26, 2011
7,782
-5
3,652
Country
Viet Nam
Location
Viet Nam
After getting covid earlier this year, I am now half human half covid. And I never felt better. Zero covid is not a viable strategy. It is too expensive to test every person every day. Also, covid transmits in the air without symptoms. So it is nearly impossible to stop.
So it is nearly impossible to stop bcs you live in a failed country that not smart enough to control Covid. SG is failed state,too, she (SG) survive till now due to US's protection .

Of course Sinovacs are failed vaccine, too, thats why Sinovac can't save Singapore (SG) .

As I said, I haven't take any vaccine shots yet bcs I don't wanna be a lab mouse for the current unsafe vacines, at least half of people in my city also haven't got any vaccine shots yet, Yeahh, we still go to work, kids still go to school. Nothing big happen in my city now.

Some guys here will say abt Covid cases in Ho Chi Minh city again, but there are no important factories in Ho Chi Minh city. The city is just a place for tourism and trading, plus abt 1,5 to 2 million Hoa ethnic and Chinese are living there. Ho Chi Minh city is big, but not important to VN.
 
Last edited:

Song Hong

SENIOR MEMBER
Jan 4, 2020
2,940
-21
4,401
Country
Viet Nam
Location
Singapore
So it is nearly impossible to stop bcs you live in a failed country that not smart enough to control Covid. SG is failed state,too, she (SG) survive till now due to US's protection .

Of course Sinovacs are failed vaccine, too, thats why Sinovac can't save Singapore (SG) .

As I said, I haven't take any vaccine shots yet bcs I don't wanna be a lab mouse for the current unsafe vacines, at least half of people in my city also haven't got any vaccine shots yet, Yeahh, we still go to work, kids still go to school. Nothing big happen in my city now.

Some guys here will say abt Covid cases in Ho Chi Minh city again, but there are no important factories in Ho Chi Minh city. The city is just a place for tourism and trading, plus abt 1,5 to 2 million Hoa ethnic and Chinese are living there. Ho Chi Minh city is big, but not important to VN.
2 x Sinovac + 1 x Cansino increase the antibodies 78x.
3 x Sinovac increase the antibodies 15x.
2 x Sinovac increase the antibodies 6x.

Covid pandemic will soon be over and everyone will go get China vaccine.

*************

BEIJING, Sept 7 (Reuters) - A Chinese study looking at mixing COVID-19 vaccines showed that receiving a booster shot of CanSino Biologics' vaccine after one or two doses of Sinovac Biotech's (SVA.O) vaccine yielded a much stronger antibody response than using the Sinovac shot as a booster.

The study, among the first analyses in China combing different COVID-19 vaccines, comes as the country said it would use booster shots in specific groups amid concerns over vaccines' waning protection over time.

Participants who received a CanSinoBIO (6185.HK), booster dose three to six months after a second Sinovac shot showed a 78-fold jump on average in neutralizing antibody levels two weeks later, according to a paper published on Monday before a peer review.

By contrast, those who received a Sinovac booster shot showed a 15.2-fold increase in neutralizing antibody levels, researchers from local disease control authorities, CanSinoBIO and other Chinese institutions said in the paper.


One dose of Sinovac followed by a CanSinoBIO booster at intervals of one or two months led to a 25.7-fold increase in neutralising antibody levels, while two doses of Sinovac induced a 6.2-fold increase.

The study analysed data from about 300 healthy adults aged 18-59.

The study did not assess the boosters' protection against COVID-19 and did not test the neutralising antibody against the more transmissible Delta variant, the paper said.

More than 1.4 billion doses of the Sinovac vaccine have been administered globally, about three quarters of them in China.


 

Viva_Viet

SENIOR MEMBER
Jun 26, 2011
7,782
-5
3,652
Country
Viet Nam
Location
Viet Nam
2 x Sinovac + 1 x Cansino increase the antibodies 78x.
3 x Sinovac increase the antibodies 15x.
2 x Sinovac increase the antibodies 6x.

Covid pandemic will soon be over and everyone will go get China vaccine.

*************

BEIJING, Sept 7 (Reuters) - A Chinese study looking at mixing COVID-19 vaccines showed that receiving a booster shot of CanSino Biologics' vaccine after one or two doses of Sinovac Biotech's (SVA.O) vaccine yielded a much stronger antibody response than using the Sinovac shot as a booster.

The study, among the first analyses in China combing different COVID-19 vaccines, comes as the country said it would use booster shots in specific groups amid concerns over vaccines' waning protection over time.

Participants who received a CanSinoBIO (6185.HK), booster dose three to six months after a second Sinovac shot showed a 78-fold jump on average in neutralizing antibody levels two weeks later, according to a paper published on Monday before a peer review.

By contrast, those who received a Sinovac booster shot showed a 15.2-fold increase in neutralizing antibody levels, researchers from local disease control authorities, CanSinoBIO and other Chinese institutions said in the paper.


One dose of Sinovac followed by a CanSinoBIO booster at intervals of one or two months led to a 25.7-fold increase in neutralising antibody levels, while two doses of Sinovac induced a 6.2-fold increase.

The study analysed data from about 300 healthy adults aged 18-59.

The study did not assess the boosters' protection against COVID-19 and did not test the neutralising antibody against the more transmissible Delta variant, the paper said.

More than 1.4 billion doses of the Sinovac vaccine have been administered globally, about three quarters of them in China.


If u r in VN, pls come to Bac Ninh (having Samsung factories ) and Bac Giang (having Luxshare factories manufacturing Ipod), then u can see that many people there haven't got enough 2 vaccine shots yet, but Covid situation is under control.
 

8888888888888

FULL MEMBER
Nov 29, 2016
1,977
0
1,928
Country
China
Location
China
China Delta Vaccine is coming Soon.

China's Clover Biopharma to launch protein-based COVID-19 vaccine by 2021-end

13 September 2021 | News


SCB-2019 is anticipated to potentially be one of the first protein-based COVID-19 vaccines commercialized globally through the COVAX Facility



image credit- shutterstock

image credit- shutterstock




China-based Clover Biopharmaceuticals has announced that its wholly-owned subsidiary, Zhejiang Clover Biopharmaceutical, Inc., has received a Pharmaceutical Manufacturing Permit from the Zhejiang Medical Products Administration for the production of Clover’s protein-based COVID-19 vaccine candidate at its facility in Changxing, Zhejiang province, China (Changxing facility).
Clover’s in-house, commercial-ready biologics manufacturing Changxing facility has a centrally-automated and flexible start-to-finish platform based on single-use technologies.
The Changxing facility was designed to adhere to current Good Manufacturing Practices (cGMP) standards in accordance with NMPA, FDA, and EMA regulations. At peak capacity, the Changxing facility will have the potential to annually produce more than one billion doses of antigen for Clover’s COVID-19 vaccine candidate, SCB-2019.
Pending positive results from SPECTRA, Clover’s global pivotal Phase 2/3 clinical COVID-19 vaccine candidate trial, the Company plans to submit conditional regulatory approval applications for SCB-2019 (CpG 1018/Alum) to the NMPA, EMA, and WHO thereafter. Pending conditional approval, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) which may occur as early as year-end 2021.

 

Tai Hai Chen

ELITE MEMBER
Oct 15, 2017
20,931
-23
9,808
Country
Canada
Location
Canada
China Delta Vaccine is coming Soon.

China's Clover Biopharma to launch protein-based COVID-19 vaccine by 2021-end

13 September 2021 | News


SCB-2019 is anticipated to potentially be one of the first protein-based COVID-19 vaccines commercialized globally through the COVAX Facility



image credit- shutterstock

image credit- shutterstock




China-based Clover Biopharmaceuticals has announced that its wholly-owned subsidiary, Zhejiang Clover Biopharmaceutical, Inc., has received a Pharmaceutical Manufacturing Permit from the Zhejiang Medical Products Administration for the production of Clover’s protein-based COVID-19 vaccine candidate at its facility in Changxing, Zhejiang province, China (Changxing facility).
Clover’s in-house, commercial-ready biologics manufacturing Changxing facility has a centrally-automated and flexible start-to-finish platform based on single-use technologies.
The Changxing facility was designed to adhere to current Good Manufacturing Practices (cGMP) standards in accordance with NMPA, FDA, and EMA regulations. At peak capacity, the Changxing facility will have the potential to annually produce more than one billion doses of antigen for Clover’s COVID-19 vaccine candidate, SCB-2019.
Pending positive results from SPECTRA, Clover’s global pivotal Phase 2/3 clinical COVID-19 vaccine candidate trial, the Company plans to submit conditional regulatory approval applications for SCB-2019 (CpG 1018/Alum) to the NMPA, EMA, and WHO thereafter. Pending conditional approval, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) which may occur as early as year-end 2021.

Clover is a very ineffective vax. Only 67% effective after 2 doses. And it uses the same crap Dynavax adjuvant Sinovac uses.
 

Mista

SENIOR MEMBER
Jun 9, 2016
3,661
7
3,117
Country
Singapore
Location
Singapore
Singapore uses western mRNA vaccines a lot. No wonder they don't trust western mRNA vaccines in China.
Lol. Data from countries which administered both mRNA and Sinovac consistently showed that Sinovac is even less effective than mRNA (Pfizer) and AZ vaccines in dealing with Delta and non-Delta variants.

Chile (non-Delta):
SANTIAGO, Aug 3 (Reuters) - Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic illness among millions of Chileans who received it between February and July, the Chilean health authorities said on Tuesday, while Pfizer's COVID-19 shot was 87.7% effective and AstraZeneca's was 68.7% effective.
...
That vaccine was 86% effective in preventing hospitalization, 89.7% effective in preventing admission to intensive care units and 86% effective in preventing deaths within the population between February and July, health official Dr Rafael Araos said in a press conference on Tuesday.
...

Pfizer's vaccine was 87.7% effective in preventing symptomatic COVID-19 in the same period, 98% effective in preventing intensive care admission and 100% effective in preventing death, Araos said.

AstraZeneca's was 68.7% effective in preventing symptomatic COVID-19 in the same period, 98% effective in preventing intensive care admissions and 100% effective in preventing death, Araos said.


Chile's study examined the vaccines' effectiveness among different cohorts of people who either received two doses of the specified vaccine, partial doses of the vaccine or no vaccine at all.

The CoronaVac part of the study examined a group of 8.6 million people, the Pfizer BioNTech part studied a group of 4.5 million people and the AstraZeneca part looked at a group of 2.3 million people.

Malaysia (Delta):
KUALA LUMPUR, Sept 24 (Reuters) - Sinovac's (SVA.O) COVID-19 vaccine is highly effective against serious illness, although rival shots from Pfizer/BioNTech and AstraZeneca showed better protection rates, a large real world study from Malaysia showed.

The latest data is a boost to the Chinese firm, whose COVID-19 vaccine has been under growing scrutiny over its effectiveness following reports of infections among healthcare workers fully immunized with the Sinovac shot in Indonesia and Thailand. read more

The study, conducted by the Malaysian government, found that 0.011% of about 7.2 million recipients of the Sinovac shot required treatment in intensive care units (ICU) for COVID-19 infections, health officials told reporters on Thursday.

By contrast, 0.002% of about 6.5 million recipients of the Pfizer (PFE.N)/BioNTech (22UAy.DE) vaccine needed ICU treatment for COVID-19 infections, while 0.001% of 744,958 recipients of the AstraZeneca (AZN.L) shot required similar treatment.

We would've been worse off if we used Sinovac.
 

8888888888888

FULL MEMBER
Nov 29, 2016
1,977
0
1,928
Country
China
Location
China
Lol. Data from countries which administered both mRNA and Sinovac consistently showed that Sinovac is even less effective than mRNA (Pfizer) and AZ vaccines in dealing with Delta and non-Delta variants.

Chile (non-Delta):


Malaysia (Delta):


We would've been worse off if we used Sinovac.
I will just leave this link here about reuters

 

Song Hong

SENIOR MEMBER
Jan 4, 2020
2,940
-21
4,401
Country
Viet Nam
Location
Singapore
Singapore got a super weapon against Covid19 if things run out of control. As per in the past, suddenly one Chinese clown will be caught verbally abusing minorities. Then GoS will shout Chinese racists menacing Singapore.

Entire country will rabid witchhunt against Chinese racists.
 

Mista

SENIOR MEMBER
Jun 9, 2016
3,661
7
3,117
Country
Singapore
Location
Singapore
I will just leave this link here about reuters

What a lameass argument.

The sources Reuters cited are straight from the health authorities in their respective countries or from medical journals.

Want me to cite you other sources?


Out of the 14,500,984 people who are fully inoculated, 1,445 have died.

Of the 1,445 deaths, 1,108 have been fully vaccinated with the Sinovac vaccine. This is out of 7.2 million people fully vaccinated with Sinovac, or a rate of 0.015%.

Another 323 breakthrough deaths were Pfizer recipients, out of 6.5 million people who have been fully inoculated with Pfizer in the country (0.005%).

The AstraZeneca vaccine had 14 breakthrough deaths, out of 744,958 recipients of the vaccine - a rate of 0.002%.


A study in Chile published this month in The New England Journal of Medicine found the Sinovac shot CoronaVac was effective in preventing infection by 65.9 per cent, hospitalisation by 87.5 per cent, ICU admission by 90.3 per cent, and death by 86.3 per cent.

The Chilean government last month released a report that found CoronaVac was 58.5 per cent effective against symptomatic illness, compared with 87.7 per cent for Pfizer-BioNTech’s vaccine and 68.7 per cent for AstraZeneca’s.
For those in that age group who tested positive for Covid-19, the death rate was 1.53 per cent for patients vaccinated with Sinopharm’s shot, 0.79 for those given the Russian Sputnik V, 0.69 for those with Pfizer-BioNTech’s vaccine and zero for those given AstraZeneca vaccine. The intensive care unit (ICU) admission rate was 1.7 per cent for Sinopharm, 0.23 per cent for Pfizer-BioNTech, 0.17 per cent for AstraZeneca and zero for Sputnik.


In Brazil, where the Gamma variant has been prevalent, a study published last month involving 76 million vaccinated people found that the AstraZeneca vaccine offered about 90 per cent effectiveness against hospitalisation, ICU admission and death, while the vaccine produced by Sinovac, another Chinese developer, provided about 75 per cent such protection.
 

Users Who Are Viewing This Thread (Total: 1, Members: 0, Guests: 1)


Top Bottom